摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5-methyl-5-hydroxyhexyl)-3,7-dimethylxanthine

中文名称
——
中文别名
——
英文名称
1-(5-methyl-5-hydroxyhexyl)-3,7-dimethylxanthine
英文别名
A 802710;1-(5-Hydroxy-5-methylhexyl)-3,7-dimethylxanthine;1-(5-hydroxy-5-methylhexyl)-3,7-dimethylpurine-2,6-dione
1-(5-methyl-5-hydroxyhexyl)-3,7-dimethylxanthine化学式
CAS
——
化学式
C14H22N4O3
mdl
——
分子量
294.354
InChiKey
ORHCPMZXZQJXJY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    78.7
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Tertiary hydroxyalkylxanthines, medicaments containing them and their use
    摘要:
    具有一般式(I)的三级羟基烷基黄嘌呤,其特征在于至少有一个残基R.sup.1和R.sup.3代表公式(Ia)的三级羟基烷基,其中R.sup.4代表具有2到5个整数的碳数不超过3的烷基;另一个残基可以保留为R.sup.1或R.sup.3,是氢原子或具有不超过6个碳原子的脂肪烃基R.sup.5,在其中碳链可以被最多两个氧原子分离或被氧代基或最多两个羟基取代,R.sup.2代表具有1到4个碳原子的烷基。还描述了一种制造这些化合物的方法,这些化合物适用于制造药物,特别是用于预防和/或治疗周围和/或脑灌注障碍。 ##STR1##
    公开号:
    US04833146A1
点击查看最新优质反应信息

文献信息

  • Substituted xanthine derivatives
    申请人:Tung Roger D.
    公开号:US20090239886A1
    公开(公告)日:2009-09-24
    This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    本发明涉及新型化合物,即取代黄嘌呤生物及其药学上可接受的盐。例如,本发明涉及新型取代黄嘌呤生物,它们是戊酰异丙基黄嘌呤的衍生物。本发明还提供了包含本发明中的一种或多种化合物和载体的组合物,以及把所述化合物和组合物用于治疗戊酰异丙基黄嘌呤和相关化合物有益的疾病和病况的方法。
  • SUBSTITUTED XANTHINE DERIVATIVES
    申请人:Tung Roger D.
    公开号:US20140121226A1
    公开(公告)日:2014-05-01
    This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula: wherein the values of R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are described herein.
    本发明涉及新型的代化合物,其为取代黄嘌呤生物和其药学上可接受的盐。具体而言,本发明涉及一种新型的取代黄嘌呤生物,其为戊酰茶碱代谢产物的代衍生物。本发明还提供包含本发明中一种或多种化合物和载体的组合物以及在治疗戊酰茶碱和相关化合物有益的疾病和病症的方法中使用所述的代化合物和组合物。本发明的化合物由以下结构式表示:其中R1,R2,R3,R4,R5,Y1和Y2的值如本文所述。
  • Modulation of cellular response to external stimuli
    申请人:Fred Hutchinson Cancer Research Center
    公开号:EP1214938A2
    公开(公告)日:2002-06-19
    The present invention relates to novel uses of xanthine derivatives, more particularly pentoxiffyline, derivatives or metabolites thereof, alone or in combination with cytochrome P450 inhibitors, such as e.g. ciprofloxacin. They may be used for treating tumors, hormone-related disorders, neurological or auto immune diseases, for treating patients undergoing bone marrow transplantation or receiving toxic agents. They are useful in modulating the effects of internal and external stimuli on cells by reversing the effects of these stimuli on the short-term secondary messenger pathways. In particular, the compounds of Formula (I), lower elevated levels of unsaturated, non-arachidonate phosphatidic acid (PA) and diacylglycerol (DAG) derived from said PA within seconds of the primary stimulus and their contact with said cells. The modulatory effect depends on the nature of the target cell and the stimulus applied.
    本发明涉及黄嘌呤生物的新用途,特别是戊氧芬碱、其衍生物或代谢物,单独使用或与细胞色素P450抑制剂(如环丙沙星)联合使用。它们可用于治疗肿瘤、激素相关疾病、神经系统疾病或自身免疫疾病,也可用于治疗接受骨髓移植或接受毒性药物治疗的患者。它们可以通过逆转内部和外部刺激对短期次级信使途径的影响来调节这些刺激对细胞的影响。特别是,式(I)化合物可在主要刺激发生后数秒内降低不饱和、非游离基酸性磷脂酸(PA)和由所述 PA 衍生的二酰甘油DAG)的升高平,并降低它们与所述细胞的接触。调节效果取决于目标细胞的性质和所施加的刺激。
  • TERTIÄRE HYDROXYALKYLXANTHINE, VERFAHREN ZU IHRER HERSTELLUNG, DIE SIE ENTHALTENDEN ARZNEIMITTEL UND IHRE VERWENDUNG
    申请人:HOECHST AKTIENGESELLSCHAFT
    公开号:EP0268585B1
    公开(公告)日:1990-05-30
  • MODULATION OF CELLULAR RESPONSE TO EXTERNAL STIMULI
    申请人:Fred Hutchinson Cancer Research Center
    公开号:EP0573617A1
    公开(公告)日:1993-12-15
查看更多